Prometheus Laboratories has launched a new PredictrPK IFX test designed to aid healthcare providers optimize therapeutic dose for patients being treated with infliximab for inflammatory bowel disease (IBD).
PredictrPK IFX combines serology markers, patient-specific variables, current dosing information, and a proprietary machine-learning algorithm to provide individualized actionable insights to optimize the dose and interval for IBD patients being treated with infliximab or its biosimilars, the company said.
The test is currently validated for IBD steady-state maintenance patients treated for ≥ 14 continuous weeks with infliximab therapy and can be performed as early as 20 days after the last infusion, according to Prometheus. Test results include current infliximab, antibody, and albumin levels, as well as estimated serum infliximab levels based on current dose and interval, and pharmacokinetic-guided doses and intervals, Prometheus said.
PredictrPK IFX is the first in a family of PredictrPK tests, and trials are underway to expand use of the test to earlier in patient management, said Dr. Thierry Dervieux, PhD, chief scientific officer at Prometheus, in a news release.